The research group has developed new ocular drug delivery technology based on cyclodextrin
nanoparticles (NP). The investigators plan to develop and test this technology to help treat
diabetic macular edema (DME).
An important step in research was the invention of cyclodextrin nanoparticles, which has just
received a US patent. The investigators pre-clinical and clinical work has demonstrated the
investigators eye drop suspension with cyclodextrin nano-particles to be superior to
conventional eye drops. They increase drug absorbance into the eye and decrease systematic
distribution of the drug, hence reducing side effects. Cyclodextrin nanoparticle eye drops
deliver drugs to the posterior part of the eye, thus solving one of the biggest obstacles in
ocular pharmacology.